Antioxidative function and biodistribution of [Gd@C82(OH)22]n nanoparticles in tumor-bearing mice

Wang, Jiangxue; Chen, Chunying; Bai, Li; Yu, Hongwei; Zhao, Yuliang; Sun, Jin; Li, Yufeng; Xing, Gengmei; Yuan, Hui; Tang, Jun; Chen, Zhe; Meng, Huan; Gao, Yuxi; Ye, Chang; Chai, Zhifang; Zhu, Chunyin; Ma, Baocheng; Fang, Xiaohong; Wan, Li‐Jun

doi:10.1016/j.bcp.2005.12.001

Cited by 151 publications

(112 citation statements)

References 37 publications

Supporting

Mentioning

108

Contrasting

Order By: Relevance

“…334 Similar results obtained in the biodistribution studies of C 60 (OH) x and C 82 (OH) y showed that the biological properties would not be expected to change upon encapsulation of metal atom in the fullerene cage. 320 Toxicity.…”

Section: Iii3 Biomedical Applicationssupporting

confidence: 72%

“…For instance, the application of [Gd@C 82 (OH) 22 ] n can repair the functions of injured liver as well as kidney tissue, 334 i.e., there is a very good correlation of the effect of [Gd@C 82 (OH) 22 ] n with that of fullerenol C 60 (OH) 24 in vivo. 335 Magnetic resonance imaging is one of the most common techniques for diagnostic examination using a magnetic field and pulses of radiofrequency energy to visualize organs and structures inside the body.…”

Section: Iii3 Biomedical Applicationsmentioning

confidence: 99%

See 1 more Smart Citation

Fullerene derivatives as nano-additives in polymer composites

Penkova¹,

Acquah²,

Piotrovskiy³

et al. 2017

Russ. Chem. Rev.

View full text Add to dashboard Cite

Section: Iii3 Biomedical Applicationssupporting

confidence: 72%

Section: Iii3 Biomedical Applicationsmentioning

confidence: 99%

Fullerene derivatives as nano-additives in polymer composites

Penkova¹,

Acquah²,

Piotrovskiy³

et al. 2017

Russ. Chem. Rev.

View full text Add to dashboard Cite

“…Liver tumor model was established by subcutaneously injection of H22 tumor cells (1 Â 10 6 cells/0.2 ml) into the flank of each mouse. [12][13][14] Reagents and enzymes Pwo DNA polymerase, T 4 DNA ligase, Klenow enzyme and restrictive endonucleases were purchased from New England BioLabs (Hertfordshire, UK). Monoclonal mouse anti-human endostatin antibody was obtained from Oncogene Research Products (San Diego, USA).…”

Section: Animals and Tumorsmentioning

confidence: 99%

A new expression plasmid in Bifidobacterium longum as a delivery system of endostatin for cancer gene therapy

et al. 2006

Cancer Gene Ther

View full text Add to dashboard Cite

To utilize Bifidobacterium longum (B. longum) as a safe and stable delivery system for endostatin in cancer gene therapy, we constructed pBV22210 vector combining a chloramphenicol-resistance gene (Cm r ) from pBCSK( þ ) plasmid, a cryptic plasmid pMB1 from B. longum strain with pBV222. Endostatin was cloned directly downstream of an N terminal His6-tag sequence in the pBV22210, so that the endostatin protein expressed in B. longum could be purified with Ni-binding resin. The results indicated that the plasmid electroporated into B. longum was maintained stably in the absence of selective antibiotics and did not significantly affect biological characteristics of B. longum. In addition, the plasmid in B. longum showed a strong inhibitory effect on the growth of mouse solid liver tumor in vivo. These results suggested that this new plasmid may be a stable vector in B. longum for transporting anti-cancer genes in cancer gene therapy.

show abstract

“…We have found that metallofullerene nanoparticles penetrate plasma membrane of tumor cells and result, to some degree, in shrinkage of solid tumors in vivo (19,20). As a proof of concept, we have demonstrated that the metallofullerene nanoparticles, formulated as [Gd@C 82 (OH) 22 ] n , are able to effectively inhibit proliferation of solid tumors and to decrease the activities of those enzymes responsible for catalyzing the production of reactive oxygen species in vivo (20)(21)(22) (OH) 22 ] n , synthesized by our group, has been verified as a new generation of highly efficient contrast agents for magnetic resonance imaging (MRI) (24-27). It is a hydroxylated fullerene forming a cage encapsulating gadolinium inside (Fig.…”

mentioning

confidence: 91%

Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis

Lü

Meng

Wang

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

235

160

View full text Add to dashboard Cite

Cisplatin is a chemotherapeutic drug commonly used in clinics. However, acquired resistance confines its application in chemotherapeutics. To overcome the acquired resistance to cisplatin, it is reasoned, based on our previous findings of mediation of cellular responses by [Gd@C 82 (OH) 22 ] n nanoparticles, that [Gd@C 82 (OH) 22 ] n may reverse tumor resistance to cisplatin by reactivating the impaired endocytosis of cisplatin-resistant human prostate cancer (CP-r) cells. Here we report that exposure of the CP-r PC-3-luc cells to cisplatin in the presence of nontoxic [Gd@C 82 (OH) 22 ] n not only decreased the number of surviving CP-r cells but also inhibited growth of the CP-r tumors in athymic nude mice as measured by both optical and MRI. Labeling the CP-r PC-3 cells with transferrin, an endocytotic marker, demonstrated that pretreatment of the CPr PC-3-luc cells with [Gd@C 82 (OH) 22 ] n enhanced intracellular accumulation of cisplatin and formation of cisplatin-DNA adducts by restoring the defective endocytosis of the CP-r cancer cells. The results suggest that [Gd@C 82 (OH) 22 ] n nanoparticles overcome tumor resistance to cisplatin by increasing its intracellular accumulation through the mechanism of restoring defective endocytosis. The technology can be extended to other challenges related to multidrug resistance often found in cancer treatments.A s a major chemotherapeutic agent for tumor treatment, cisplatin remains a cornerstone of the present-day chemotherapy regimens against not only epithelial malignancies but also a number of metastatic and advanced malignancies (1, 2). However, because of high toxicity and easy development of drug resistance, successful treatment with cisplatin often is limited (3,4). Following the discovery of ATP-binding cassette (ABC) transporters and their roles in drug resistance in various types of tumors (5), much research has been done to explore the relationship between ABC transporter activity and specific chemotherapeutics, including cisplatin. Because no ABC transporter has been identified for "pumping" cisplatin out of cisplatin-resistant human prostate cancer (CP-r) cells (6-8), it would be difficult to sensitize CP-r cells by using any known strategy that targets resistant cancer cells by inhibiting multidrug resistance (MDR)-associated proteins on plasma membrane of the CP-r cells. Diffusion has been considered as a pathway for cisplatin to penetrate plasma membrane. Recently, studies have indicated that cisplatin entered cells by endocytosis and other mechanisms (9-12).To increase susceptibility of cancer cells to cisplatin, i.e., to reverse drug resistance, many efforts have been made through chemical modification, gene therapy, vector delivery, and other means (2, 9, 13). Combination of traditional chemotherapy with nanotechnology may provide a promising alternative for novel cancer treatments. The use of nanoparticles to sensitize tumor cells to cisplatin in vitro and in vivo has been described recently (14-16). In these studies, cisplatin-encap...

show abstract

Antioxidative function and biodistribution of [Gd@C82(OH)22]n nanoparticles in tumor-bearing mice

Cited by 151 publications

References 37 publications

Fullerene derivatives as nano-additives in polymer composites

Fullerene derivatives as nano-additives in polymer composites

A new expression plasmid in Bifidobacterium longum as a delivery system of endostatin for cancer gene therapy

Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis

Contact Info

Product

Resources

About